Synopsis A recent clinical study demonstrates the efficacy and safety of sodium thiosulfate reduce the incidence and severity of Cisplatin-induced hearing loss. The present study aims to assess the efficacy of sodium thiosulfate (STS) to reduce the hearing impairment caused by cisplatin chemotherapy. This week’s “MED FACT” discusses a clinical trial from The New England Journal of Medicine, “ Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss” . June 21, 2018. Authors : P.R. Brock; R.
Maibach; M. Childs; et. al. Key Takeaways: The addition of delayed sodium thiosulfate to cisplatin led to a 48% lower risk of hearing loss. Objective: To evaluate the efficacy and safety of sodium thiosulfate in cisplatin-induced ototoxicity Study Type: International, prospective, randomized trial Participants: 109 What was the need for this study? Sodium thiosulfate may protect…
